Last reviewed · How we verify
Ivermectin 1% cream (IVM)
Ivermectin binds to glutamate-gated chloride channels in parasites and arthropods, causing paralysis and death of the organisms.
Ivermectin binds to glutamate-gated chloride channels in parasites and arthropods, causing paralysis and death of the organisms. Used for Rosacea (topical), Scabies (topical).
At a glance
| Generic name | Ivermectin 1% cream (IVM) |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Antiparasitic agent |
| Target | Glutamate-gated chloride channels (invertebrate-specific) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Ivermectin is an antiparasitic agent that selectively binds to invertebrate-specific glutamate-gated chloride ion channels, increasing chloride conductance and causing hyperpolarization of nerve and muscle cells. This leads to paralysis and death of susceptible parasites and arthropods. In topical cream formulation, it is used to treat skin conditions caused by parasitic mites and inflammatory responses to parasitic infestation.
Approved indications
- Rosacea (topical)
- Scabies (topical)
Common side effects
- Skin irritation
- Erythema
- Pruritus
- Burning sensation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivermectin 1% cream (IVM) CI brief — competitive landscape report
- Ivermectin 1% cream (IVM) updates RSS · CI watch RSS
- Galderma R&D portfolio CI